@article{JTD22438,
author = {Ke-Xing Xi and Xue-Wen Zhang and Xiang-Yang Yu and Wei-Dong Wang and Ke-Xiang Xi and Yong-Qiang Chen and Ying-Sheng Wen and Lan-Jun Zhang},
title = {The role of plasma miRNAs in the diagnosis of pulmonary nodules},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {7},
year = {2018},
keywords = {},
abstract = {Background: In this study, we aimed to assess the clinical utility of detection of plasma microRNAs (miRNAs) in the diagnosis of pulmonary nodules.
Methods: Fifty-seven patients with pulmonary nodules who had undergone surgery were enrolled in our study from July 2016 to July 2017 at Sun Yat-sen University Cancer Center. We measured the expression levels of 12 miRNAs (miRNA-17, -146a, -200b, -182, -155, -221, -205, -126, -7, -21, -145, and miRNA-210) in plasma samples of 57 patients, including 15 benign pulmonary nodules patients and 42 malignant pulmonary nodules patients. The levels of these miRNAs were detected by Real-time quantitative polymerase chain reaction (RT-PCR). The receiver operating characteristic (ROC) curve was used to assess the diagnostic performance of plasma miRNAs for non-small cell lung cancer (NSCLC).
Results: The expression levels of plasma miRNA-17, -146a, -200b, -182, -155, -221, -205, -126, -7, -21, -145, and miRNA-210 are not associated with gender, age, pTNM stage, differentiation grade. The levels of miRNA-17, -146a, -200b, -182, -221, -205, -7, -21, -145, and miRNA-210 in NSCLC patients are significantly higher than those in benign pulmonary nodules patients (P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/22438}
}